Sentences with phrase «future share price increases»

In addition, an IPO, as opposed to an outright sale, would allow Blackstone to hold on to a stake of the company and benefit from future share price increases, notes Dan Fasulo, managing director with Real Capital Analytics (RCA), a New York City - based research firm.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Some investors argue that massive share - price increases in 2014 mean that even future successes won't produce strong returns for shareholders buying in at today's prices, but the demand among top pharmaceutical companies for promising drug candidates to add to their pipelines shows few signs of slowing anytime soon, and that could bode well for the sector in the coming year.

If they wanted to increase their shares of stock and lower prices so that future buyers are not paying as much, they could simply take the 10,000,000 shares, but the price in half, and now have 20,000,000 shares.

Consequently, I continue to invest in young prospects who I believe will be subject to a significant share price rise in the future, on account of not only their improved ability, but also their increased popularity as a result.

However, both years bonuses could in theory be worth much more than they are now if the banks share price increases in the future.

«Because it allows them to consolidate their market share» says Kate Poole, deputy chief executive of the Society of Authors, «then in future when they may increase the price»

In addition to having a better dividend history and projected future increase in the share price by Wall Street, Nucor is also carrying less debt.

The hope is that the stock price will increase from $ 150 a share to something higher in the future.

Stocks trade at prices based on future expectations and speculation, so that means if traders expect a company to double its profits next year, the share price could easily double (there are reasons it might not increase so much, and there are reasons it could increase even more than that, but that's not the point).

However we just calculated that $ 7,333.34 [$ 6,666.67 + 10 % share price increase cushion] is needed to qualify for a single reinvested dividend share in future quarters.

Growth companies such as Google are expected to increase their profits markedly in the future; thus, the market bids up their share prices to high valuations.

When there is an increase in interest rates, the present value of future dividend payments decreases, and thus, the price of a preferred share would be expected to fall.

Discover why UWTI has performed a reverse split to increase the fund's price per share and why it is likely to happen again in the future.